-
1.发明公开公开(公告)号：US20230377764A1
公开(公告)日：2023-11-23
申请号：US18164164
申请日：2023-02-03
IPC分类号： G21F5/12 , A61P35/00 , A61K9/00 , A61K38/18 , A61K38/19 , A61K38/36 , A61K39/395 , A61K45/06 , C07K14/475 , C07K14/52 , C07K14/755 , C07K16/28 , G21F7/005
CPC分类号： G21F5/12 , A61P35/00 , A61K9/0019 , A61K38/18 , A61K38/195 , A61K38/36 , A61K39/3955 , A61K45/06 , C07K14/475 , C07K14/522 , C07K14/755 , C07K16/2818 , C07K16/2827 , C07K16/2878 , G21F7/005 , A61K2039/507
摘要： The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.
-
公开(公告)号：US20220298225A1
公开(公告)日：2022-09-22
申请号：US17596118
申请日：2020-06-03
发明人： Jeffrey A. HUBBELL , Jun ISHIHARA , Koichi SASAKI
IPC分类号： C07K14/745 , A61K47/64 , A61P35/00 , A61K45/06 , A61K38/36 , A61K39/395
摘要： This disclosure relates to tumor-targeted drug carriers that lead to improved anti-tumor efficacy by efficient delivery of a cytotoxic agent to the tumor microenvironment. Aspects of the disclosure relate to a polypeptide comprising an albumin or IgG Fc domain polypeptide operatively linked to a collagen binding domain. Further aspects relate to a composition comprising a polypeptide, nucleic acid, or cell of the disclosure.
-
公开(公告)号：US20240052006A1
公开(公告)日：2024-02-15
申请号：US18246512
申请日：2021-09-24
发明人： Jeffrey A HUBBELL , Eiji YUBA , Elyse WATKINS , Jun ISHIHARA , Ako ISHIHARA , Erica BUDINA , Abigail LAUTERBACH
CPC分类号： C07K14/54 , A61P37/02 , C12N15/63 , C07K2319/31
摘要： Aspects of the present disclosure provide methods and compositions for treatment of autoimmune disorders including, for example, multiple sclerosis and rheumatoid arthritis. Also disclosed are methods for promoting wound healing. Certain aspects are directed to antiinflammatory cytokines operatively linked to an albumin protein. Further aspects relate to methods for delivering an anti-inflammatory cytokine to a lymph node.
-
公开(公告)号：US20210040179A1
公开(公告)日：2021-02-11
申请号：US15733085
申请日：2018-11-13
发明人： Jeffrey A. HUBBELL , Anna M. RANDI , Jun ISHIHARA , Ako ISHIHARA , Priscilla BRIQUEZ , Richard STARKE
摘要： The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80% identical to one of SEQ ID NOS:1-7, 13-15, 49-50, or 66-70, or a fragment thereof; wherein the peptide is less than 300 amino acids in length.
-
公开(公告)号：US20220281936A1
公开(公告)日：2022-09-08
申请号：US17597793
申请日：2020-07-24
发明人： Jeffrey HUBBELL , Jun ISHIHARA , Juan MENDOZA , Aslan MANSUROV
IPC分类号： C07K14/54 , C07K14/715 , A61K47/68 , A61K39/395 , A61P35/00
摘要： he disclosure relates to the engineering of collagen-binding modification of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which unmasks the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Accordingly, aspects of the disclosure relate to a polypeptide comprising a therapeutic agent linked to a masking agent through a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the association of the therapeutic agent to its therapeutic target, and further wherein the polypeptide is operatively linked to a collagen binding domain or a tumor-targeting agent.
-
6.发明申请公开(公告)号：US20210094995A1
公开(公告)日：2021-04-01
申请号：US15733582
申请日：2019-03-05
发明人： Jeffrey A. HUBBELL , Jun ISHIHARA , Ako ISHIHARA , Koichi SASAKI , Melody SWARTZ , Aslan MANSUROV
摘要： The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.
-
公开(公告)号：US20240228586A1
公开(公告)日：2024-07-11
申请号：US18559180
申请日：2022-05-05
发明人： Jeffrey HUBBELL , Jun ISHIHARA , Juan MENDOZA , Aslan MANSUROV
IPC分类号： C07K14/715 , A61K38/17 , A61K38/20 , A61K38/21 , A61K39/395 , A61K47/64 , A61K47/68 , A61P35/00 , C07K14/47 , C07K14/54 , C07K14/55 , C07K14/57
CPC分类号： C07K14/7155 , A61K38/1709 , A61K38/1793 , A61K38/2013 , A61K38/208 , A61K38/217 , A61K39/395 , A61K47/643 , A61K47/6843 , A61P35/00 , C07K14/47 , C07K14/5434 , C07K14/55 , C07K14/57 , C07K14/7156 , C07K2319/50
摘要： The disclosure relates to the engineering of collagen-binding modification of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which unmasks the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Accordingly, aspects of the disclosure relate to a polypeptide comprising a therapeutic agent linked to a masking agent through a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the association of the therapeutic agent to its therapeutic target, and further wherein the polypeptide is operatively linked to a collagen binding domain or a tumor-targeting agent.
-
公开(公告)号：US20240092867A1
公开(公告)日：2024-03-21
申请号：US18352101
申请日：2023-07-13
发明人： Jeffrey A. HUBBELL , Anna M. RANDI , Jun ISHIHARA , Ako ISHIHARA , Priscilla BRIQUEZ , Richard STARKE
IPC分类号： C07K14/78 , A61K9/00 , A61K9/70 , A61K38/00 , A61K38/18 , A61K38/39 , A61K47/64 , A61K47/69 , A61L27/22 , A61P17/02 , C07K14/475 , C07K14/705 , C07K14/81 , C07K16/18
CPC分类号： C07K14/78 , A61K9/0024 , A61K9/7007 , A61K38/00 , A61K38/18 , A61K38/39 , A61K47/6435 , A61K47/6903 , A61L27/22 , A61P17/02 , C07K14/475 , C07K14/70546 , C07K14/8121 , C07K16/18 , A61L2300/412 , C07K2317/55 , C07K2319/70
摘要： The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80% identical to one of SEQ ID NOS:1-7, 13-15, 49-50, or 66-70, or a fragment thereof; wherein the peptide is less than 300 amino acids in length.
-
公开(公告)号：US20220118089A1
公开(公告)日：2022-04-21
申请号：US17310802
申请日：2020-02-25
IPC分类号： A61K39/44 , A61K47/64 , A61K38/20 , A61K38/21 , A61K38/18 , A61K38/19 , A61K38/17 , A61P37/06
摘要： The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases. Accordingly, embodiments of the disclosure relate to a composition comprising an anti-inflammatory agent operatively linked to an extracellular matrix (ECM)-affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to a serum protein and/or an ECM-affinity peptide. Further aspects of the disclosure relate to a method for treating an autoimmune or inflammatory condition in a subject comprising administering a composition of the disclosure to the subject.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
